Kane Biotech Inc.
KNBIF
$0.02
$0.00-8.08%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 49.29% | 10.78% | -103.75% | 17.99% | 33.48% |
| Total Depreciation and Amortization | -48.90% | -22.65% | -15.62% | -16.96% | 5.83% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -106.48% | -89.05% | 98.80% | -10.45% | -25.52% |
| Change in Net Operating Assets | -170.50% | -34.70% | 68.84% | -186.70% | -8.58% |
| Cash from Operations | -62.79% | -28.49% | 64.76% | -5.34% | 48.35% |
| Capital Expenditure | 100.00% | 100.00% | -- | -152.63% | 31.91% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 95.83% | -101.15% | 90.44% | -102.43% | -162.43% |
| Cash from Investing | -169.47% | 737.10% | -100.45% | -103.50% | -96.23% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 88.66% | 86.09% | 98.16% | 19.89% | -1.11% |
| Issuance of Common Stock | 86.12% | -100.00% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 254.48% | 36.96% | 97.17% | 93.80% | -103.27% |
| Cash from Financing | 229.49% | -136.87% | 125.26% | 400.57% | -18.24% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 79.79% | -43.36% | 259.55% | 168.49% | -167.93% |